Bronchial

Cardiac depressants, probably affecting the heart muscle and to some degree vagal inhibition. The extent to which the vaso-motor system participates in first causing increased and then lowered blood pressure is not satisfactorily known. Full doses cause cardiac arrythmia, and increase the number of heartbeats greatly, but render them weaker. The uterus, spleen, and bronchi contract under the influence of these drugs. Temperature, though at first considerably increased, falls when sweating has become well established. This action is more marked during fevers than in health. After the termination of sweating temperature regains its normal status, usually at once, but is sometimes delayed for several hours. As a rule, the secretion of milk is believed to be unaffected by pilocarpine, but contrary to what might be anticipated, where there is a diminished lacteal secretion, it apparently increases the supply. One or two drachms of powdered jaborandi infused in a cupful of boiling water and taken at one dose will in about ten to twenty minutes cause a tingling of the skin with marked redness of the surface. This sensation is first experienced in the face, but soon extends to the whole surface of the body, and is quickly followed by an abundant perspiration, which is apt to last for four or five hours. Almost simultaneously with the sweating the secretion of saliva increases to such an extent as to greatly embarrass speech, the person being obliged to assume an inclined position that the escape of saliva may be facilitated. During this stage from one to two pints of saliva and even more may be secreted, and usually there will be in addition an augmentation of the bronchial and lachrimal flow. The saliva contains an abundance of ptyalin and salts and readily converts starch into sugar. At times the mucous glands of the intestines are so stimulated and peristalsis so increased as to cause diarrhoea, and it is not a rare circumstance that the submaxillary glands enlarge and become painful. Nausea and vomiting less likely with pilocarpine ; , vertigo, hiccough, heaviness of the head, and contraction of the pupils may take place. From the commencement of perspiration the face becomes pale, the pulse temporarily fuller and more frequent; the pulsations become irregular, and with persons laboring under cardiac affections, a kind of asystole is observed. The effects of these drugs occur more readily in adults than in children, the latter in fact standing their action much better than adults. In using these medicines to produce diaphoresis it is not necessary to use warm drinks or other usual aids toward facilitating the sweating. During the sudorific action of.
URTI. The operational definition of recurrent URTIs was 2 separate episodes mo over the preceding 612 mo 17 ; . URTIs included coryza, rhinitis, acute sinusitis, pharyngitis, tonsillitis, laryngitis, and tracheitis 18 ; . The symptoms elicited were runny nose, cough, sore throat, difficulty in breathing or wheeze, and earache or discharge, with or without fever. Laboratory evidence of infection consisted of 3 of the following indicators of inflammation: an erythrocyte sedimentation rate ESR ; 20 mm h, an 1-acid glycoprotein concentration 1.1 g L, a C-reactive protein concentration 10 mg L, and a white blood cell WBC ; count 9 103 mm3 1921 ; . Episodes of illness were considered separate if there were 5 symptom-free days between the episodes. The group without infection ie, the control group ; consisted of children seeking treatment for minor injuries that did not involve infection or for poor vision. These children either had no elevated values for any of the 4 laboratory tests of inflammation or had an elevated value for only 1 of the tests. Exclusion criteria Children with severe protein-energy malnutrition, a history of other systemic diseases, chronic bronchial asthma, or chronic diarrhea were excluded from the study. Children were also excluded if they had signs of an infection but had elevated values for 2 inflammatory indicators, if hemoglobin data was not available, or if the children had a hemoglobin concentration 70 g L, which indicated severe anemia at baseline 22 ; . Methods The study was a longitudinal, randomized, controlled, doubleblind supplementation trial, and the study design is shown in Figure 1. On the basis of the estimated prevalence of anemia in this age group in Sri Lanka 1 ; , the sample size was calculated to be 420, with the assumption that the prevalence of anemia in children with infection was similar to that in children without infection and with the assumption of a 20% dropout rate. Baseline before supplementation ; For each child, a detailed medical history was obtained and a clinical examination was carried out by the study pediatrician. Socioeconomic status and morbidity from respiratory and gastrointestinal illnesses 3 loose stools 24 h ; during the preceding 2 wk were recorded on pretested, interviewer-administered questionnaires. Height to the nearest 0.5 cm and weight to an accuracy of 0.5 kg Salter Balance; Salter Scales, London ; were recorded. A venous blood sample 5 mL ; was obtained from each child between 0900 and 1100 by using sterile equipment. An aliquot 2.5 mL ; was collected in tubes containing an anticoagulant EDTA ; , placed on ice, and processed within 3 h of collection. The remaining blood 2.5 mL ; was collected in a tube without anticoagulants, serum was separated by centrifugation at 3000 rpm MSE Soniprep 150; MSE Scientific Instruments, Crawley, Sussex, United Kingdom ; for 7 min at 28 C, and aliquots were stored at 20 C. The lag period between baseline measurements and the start of the intervention was 2436 h. Supplementation and follow-up Children were stratified by age and sex and were randomly assigned to receive iron or placebo on a 3: basis within each stratum. Because variation in the response to the intervention was likely to be greater in the iron group than in the placebo. There isn't a card like it graded higher. The beautiful pieces produced by Wilson Franks for only one season are notoriously susceptible to fading and staining. This card boasts an undeniable "brand new" appearance. It is perfectly centered displaying vivid color and faultless corners. Minimum bid , 500.00.

After electrophoresis, the area of gel containing the protein band to be immunofixed was overlaid with a proportionate strip of filter paper Whatman no.1 ; moistened withantiserum and left to incubate for 15 mm. After three 30.
37. de Boer, M., A. Kasran, J. Kwekkeboom, H. Walter, P. Vandenberghe, and J. L. Ceuppens. 1993. Ligation of B7 with CD28 CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur. J. Immunol. 23: 3120. 38. Skov, S., M. Bonyhadi, N. Odum, and J. A. Ledbetter. 2000. IL-2 and IL-15 regulate CD154 expression on activated CD4 T cells. J. Immunol. 164: 3500. 39. Splawski, J. B., J. Nishioka, Y. Nishioka, and P. E. Lipsky. 1996. CD40 ligand is expressed and functional on activated neonatal T cells. J. Immunol. 156: 119. 40. Gately, M. K., L. M. Renzetti, J. Magram, A. S. Stern, L. Adorini, U. Gubler, and D. H. Presky. 1998. The interleukin-12 interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16: 495. 41. Murphy, K. M., W. Ouyang, S. J. Szabo, N. G. Jacobson, M. L. Guler, J. D. Gorham, U. Gubler, and T. L. Murphy. 1999. T helper differentiation proceeds through Stat1-dependent, Stat4-dependent and Stat4-independent phases. Curr. Top. Microbiol. Immunol. 238: 13. 42. Sinigaglia, F., D. D'Ambrosio, P. Panina-Bordignon, and L. Rogge. 1999. Regulation of the IL-12 IL-12R axis: a critical step in T-helper cell differentiation and effector function. Immunol. Rev. 170: 65. 43. Rogge, L., L. Barberis-Maino, M. Biffi, N. Passini, D. H. Presky, U. Gubler, and F. Sinigaglia. 1997. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185: 825. 44. Szabo, S. J., A. S. Dighe, U. Gubler, and K. M. Murphy. 1997. Regulation of the interleukin IL ; -12R[ ]2 subunit expression in developing T helper 1 Th1 ; and Th2 cells. J. Exp. Med. 185: 817. 45. Igarashi, O., H. Yamane, S. Imajoh-Ohmi, and H. Nariuchi. 1998. IL-12 receptor IL-12R ; expression and accumulation of IL-12R 1 and IL-12R 2 mRNAs in CD4 T cells by costimulation with B72 molecules. J. Immunol. 160: 1638. 46. Yamane, H., O. Igarashi, T. Kato, and H. Nariuchi. 2000. Positive and negative regulation of IL-12 receptor expression of naive CD4 T cells by CD28 CD152 costimulation. Eur. J. Immunol. 30: 3171. 47. Park, W. R., C. S. Park, M. Tomura, H. J. Ahn, Y. Nakahira, M. Iwasaki, P. Gao, R. Abe, T. Hamaoka, and H. Fujiwara. 2001. CD28 costimulation is required not only to induce IL-12 receptor but also to render Janus kinases STAT4 responsive to IL-12 stimulation in TCR-triggered T cells. Eur. J. Immunol. 31: 1456. 48. Desai, B. B., P. M. Quinn, A. G. Wolitzky, P. K. Mongini, R. Chizzonite, and M. K. Gately. 1992. IL-12 receptor. II. Distribution and regulation of receptor expression. J. Immunol. 148: 3125. 49. Wu, C., R. R. Warrier, X. Wang, D. H. Presky, and M. K. Gately. 1997. Regulation of interleukin-12 receptor 1 chain expression and interleukin-12 binding by human peripheral blood mononuclear cells. Eur. J. Immunol. 27: 147. 50. Farrar, J. D., J. D. Smith, T. L. Murphy, and K. M. Murphy. 2000. Recruitment of Stat4 to the human interferon- receptor requires activated Stat2. J. Biol. Chem. 275: 2693. 51. Fanslow, W. C., K. N. Clifford, M. Seaman, M. R. Alderson, M. K. Spriggs, R. J. Armitage, and F. Ramsdell. 1994. Recombinant CD40 ligand exerts potent biologic effects on T cells. J. Immunol. 152: 4262. 52. Arad, G., R. Nussinovich, and R. Kaempfer. 1995. Interleukin-2 induces an early step in the activation of interferon- gene expression. Immunol. Lett. 44: 213. 53. Kasahara, T., J. J. Hooks, S. F. Dougherty, and J. J. Oppenheim. 1983. Interleukin 2-mediated immune interferon IFN- ; production by human T cells and T cell subsets. J. Immunol. 130: 1784. 54. Kubin, M., M. Kamoun, and G. Trinchieri. 1994. Interleukin 12 synergizes with B7 CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J. Exp. Med. 180: 211. 55. Murphy, E. E., G. Terres, S. E. Macatonia, C. S. Hsieh, J. Mattson, L. Lanier, M. Wysocka, G. Trinchieri, K. Murphy, and A. O'Garra. 1994. B7 and interleukin 12 cooperate for proliferation and interferon production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 180: 223. 56. Le Gros, G., S. Z. Ben-Sasson, R. Seder, F. D. Finkelman, and W. E. Paul. 1990. Generation of interleukin 4 IL-4 ; -producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J. Exp. Med. 172: 921. 57. Seder, R. A., R. N. Germain, P. S. Linsley, and W. E. Paul. 1994. CD28-mediated costimulation of interleukin 2 IL-2 ; production plays a critical role in T cell priming for IL-4 and interferon production. J. Exp. Med. 179: 299. 58. Steel, C., and T. B. Nutman. 1993. Regulation of IL-5 in onchocerciasis: a critical role for IL-2. J. Immunol. 150: 5511. 59. Van Parijs, L., A. Biuckians, A. Ibragimov, F. W. Alt, D. M. Willerford, and A. K. Abbas. 1997. Functional responses and apoptosis of CD25 IL-2R -deficient T cells expressing a transgenic antigen receptor. J. Immunol. 158: 3738. 60. Walter, H., S. Schepensn, J. Van Wauwe, and M. de Boer. 1994. Ligation of CD28 on resting T cells by its ligand B7 results in the induction of both Th1- and Th2-type cytokines. Eur. Cytokine Network 5: 13. 61. Bird, J. J., D. R. Brown, A. C. Mullen, N. H. Moskowitz, M. A. Mahowald, J. R. Sider, T. F. Gajewski, C. R. Wang, and S. L. Reiner. 1998. Helper T cell differentiation is controlled by the cell cycle. Immunity 9: 229. 62. Wells, A. D., M. C. Walsh, D. Sankaran, and L. A. Turka. 2000. T cell effector function and anergy avoidance are quantitatively linked to cell division. J. Immunol. 165: 2432. 63. Malek, T. R., B. O. Porter, E. K. Codias, P. Scibelli, and A. Yu. 2000. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J. Immunol. 164: 2905. 64. Umetsu, D. T., and R. H. DeKruyff. 1997. Th1 and Th2 CD4 cells in the pathogenesis of allergic diseases. Proc. Soc. Exp. Biol. Med. 215: 11. Anterior descending coronary artery in 50 percent of the patients, the right coronary vessel in 27 percent, and the left circumflex artery in 23 percent. Nearly all the treated lesions were class B1 or B2 according to the American College of CardiologyAmerican Heart Association classification. Although all the target index lesions were primary lesions, 1.7 percent of the patients had undergone previous coronary-artery surgery and 18.1 percent had undergone previous percutaneous interventions for the treatment of other lesions and bumetanide.
Proh-KAYN-ah-myd ; Pregnancy Category C Apo-Procainamide Procan SR Classification Antiarrhythmic, class IA See Also See also Antiarrhythmic Agents. Action Kinetics Produces a direct cardiac effect to prolong the refractory period of the atria and to a lesser extent the bundle of His-Purkinje system and ventricles. Large doses may cause AV block. Some anticholinergic and local anesthetic effects. Onset: PO, 30 min; IV, 1-5 min. Time to peak effect, PO: 90-120 min; IM, 15-60 min; IV, immediate. Duration: 3 hr. t1 2: 2.5-4.7 hr. Therapeutic serum level: 4-8 mcg mL. Protein binding: 15%. From 40% to 70% excreted unchanged. Metabolized in the liver 16%-21% by slow acetylators and 24%33% by fast acetylators ; to the active N-acetylprocainamide NAPA has antiarrhythmic properties with a longer half-life than procainamide. Uses Documented ventricular arrhythmias e.g., sustained ventricular tachycardia ; that may be life threatening in clients where benefits of treatment clearly outweigh risks. Antiarrhythmic drugs have not been shown to improve survival in clients with ventricular arrhythmias. Contraindications Hypersensitivity to drug, complete AV heart block, lupus erythematosus, torsades de pointes, asymptomatic ventricular premature contractions. Lactation. Special Concerns There is an increased risk of death in those with non-life-threatening arrhythmias. Although used in children, safety and efficacy have not been established. Use with extreme caution in clients for whom a sudden drop in BP could be detrimental, in CHF, acute ischemic heart disease, or cardiomyopathy. Also, use with caution in clients with liver or kidney dysfunction, preexisting bone marrow failure or cytopenia of any type, development of first-degree heart block while on procainamide, myasthenia gravis, and those with bronchial asthma or other respiratory disorders. May cause more hypotension in geriatric clients; also, in this population, the dose may have to be decreased due to age-related decreases in renal function. Side Effects Body as a whole: Lupus erythematosus-like syndrome especially in those on maintenance therapy and who are slow acetylators. Symptoms include arthralgia, pleural or abdominal pain, arthritis, pleural effusion, pericarditis, fever, chills, myalgia, skin lesions, hematologic changes. CV: Following IV use: Hypotension, ventricular asystole or fibrillation, partial or complete heart block. Rarely, second-degree heart block after PO use. GI: N&V, diarrhea, anorexia, bitter taste, abdominal pain. Hematologic: Thrombocytopenia, agranulocytosis neutropenia. Rarely, hemolytic anemia. Dermatologic: Urticaria, pruritus, angioneurotic edema, flushing, maculopapular rash. CNS: Depression, dizziness, weakness, giddiness, psychoses, hallucinations. Other: Granulomatous hepatitis, weakness, fever, chills. Laboratory Test Alterations May affect LFTs. False + in serum alkaline phosphatase. Positive ANA test. High levels of lidocaine and meprobamate may inhibit fluorescence of procainamide and NAPA. Overdose Management Symptoms: Plasma levels of 10-15 mcg mL are associated with toxic symptoms. Progressive widening of the QRS complex, prolonged QT or PR intervals, lowering of R and T waves, increased AV block, increased ventricular extrasystoles, ventricular tachycardia or fibrillation. IV overdose may result in hypotension, CNS depression, tremor, respiratory depression. Treatment: Induce emesis or perform gastric lavage followed by. Is stimulating; it clears sinus congestion and opens the bronchial passages. Use in a diffuser for colds and flu and also in the bath for aches and pains and buprenorphine.
CLASS: ACTIONS: INDICATIONS: Sympathomimetic. Bronchodilator, increases heart rate. Bronchial asthma, reversible bronchospasm associated with COPD, preterm labor. Patients with known hypersensitivity to the drug. Blood pressure, pulse, and EKG must be constantly monitored. Palpitations, tachycardia, and PVCs, anxiety, tremor, and headache. Metered-dose inhaler: two inhalations, 1 minute apart. Subcutaneous injection: 0.25 mg; may be repeated in 15-30 minutes. Inhalation, subcutaneous injection, IV preterm labor only ; . 0.01 mg kg subcutaneously.
In experimental protein deficiency and its correlation with nerve conduction velocities. J. Neurol. Sci. 17: 299"409. 48. KArrz, M. & AUERBACH, 1979 ; Retinal degeneration in RCS E. rats raised under ambient light levels. Vision Res. 19: 79"81 and buspirone. The hospital and community. Am. J. Epidemiol. 85: 45-60. Klein, J. O., and M. Finland. 1963. Ampicillin: activity in vitro and absorption and excretion in normal young men. Am. J. Med. Sci. 245: 544-555. Klein, J. O., and M. Finland. 1963. The new penicillins. New Engl. J. Med. 269: 1019-1025; 1074-1082; Knudsen, E. T., G. N. Rolinson, and R. Sutherland. 1967. Carbenicillin: a new semisynthetic penicillin active against Pseudomonas pyocyanea. Brit. Med. J. 2: 75-78. Pines, A., H. Raafat, and K. Plucinski. 1967. Gentamicin and colistin in chronic purulent bronchial infections. Brit. Med. J. 2: 543-545. Steers, E., E. L. Foltz, and B. S. Graves. 1959. Inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics. Antibiot. Chemotherapy 9: 307-311. Steigbigel, N. H., C. E. McCall, C. W. Reed, and M. Finland. 1967. Antibacterial action of "broad spectrum" penicillins, cephalosporins, and other antibiotics against gram-negative bacilli isolated from bacteremia patients. Ann. N.Y. Acad. Sci. 145: 224-236. van Rooyen, C. E., J. F. Ross, G. W. Bethune, and A. C. MacDonald. 1967. Bacteriological observations on carbenicillin in the control of Pseudomonas aeruginosa infection in burns. Can. Med. Assoc. J. 97: 1227-1229.
Reduced P. aeruginosa LPS induced NF-kB binding activity fig. 4a, lane 2 compared to lane 1 ; . No endogenous NF-kB binding activity was found in unstimulated-non-CF bronchial epithelial cells, as previously reported [24] data not shown ; . Exposure of CF bronchial epithelial cells to FP led to a strong downregulation of NF-kB fig. 4a, lane 4 ; . The specificity of NF-kB DNA-binding was confirmed in competition experiments. Incubation of nuclear extracts from resting CF bronchial cells with a 100-fold excess of unlabelled cold kB ; NF-kB oligonucleotide led to a complete inhibition of binding activity fig. 4b, lane 1 ; . The components of the NF-kB DNA-binding protein complex was determined by performing supershift assays with antibodies to the p65 and busulfan.

Ex-smokers who are at greatest risk of developing lung cancer i.e. over the age of 60 years ; who would be fit for resection surgery. It is imperative that any screening programme, if adopted, is linked to a smoking cessation programme see above ; . The tantalising prospect of using molecular genetic tools to screen for lung cancer is now upon us. One cell surface marker hnRNP A2 B1 ; which is up-regulated in premalignant bronchial epithelial cells, appears to be a sensitive marker of early pre-invasive malignancy compared with sputum cytology sensitivity 91%, specificity 88% ; Tockman et al, 1994 ; . Point mutations in the P53 and K-ras genes in sputum samples appear to precede clinical diagnosis of lung cancer Mao et al, 1994 ; . Genomic instability which causes micro-satellite alterations that can act as clonal markers of early malignant change has also been reported Mulshine and Henschke, 2000 ; . Fluorescent bronchoscopy which increases the sensitivity of diagnosing early cancer has also been investigated as a possible tool for earlier diagnosis Lamb et al, 1998; George, 1999. Fect, 780 Beclomethasone dipropionate, aerosol for steroid-dependent asthma, 345 and chronic asthma, 38 Biopsy, fiberoptic transbronchial, pulmonary hemorrhage in, 584 lung, how vs whom? 201 lung, open, 689 lung, percutaneous trephine, 201, 212 of peripheral pulmonary masses, ultrasonically guided percutaneous, 627 Blood groups, P system in pigeon breeders and pigeon breeder's disease, 894, 719 Blood platelets: See Platelet aggregation Blood pressure, pulmonary capillary wedge, limitations and use in cardiac tamponade, 451 pulmonary, relationship with arterial pH and C02 tension, 466 Blood transfusion, autologous, during cqrdiopulmonary bypass, 592 reduction of usage in open heart swwry, 454 Blood velocity, arterial, upstroke time, Doppler ultrasonic assessment of aortic stenosis, 48 Blood volume, systolic anterior motion of mitral valve due to hypovolemia and anemia, 687 Bone resorption in progressive systemic sclerosis, 107 Bookshelf, July PA-25, Aug p17, Sept p 26, Oct p26, Nov p26, 27, 30 Botryomywma, pulmonary, 385 Breast neoplasms, pulmonary lymphangitic carcinoma, 105 Breath, value of estimating sound intensitv. 341 ~ r e n'see Respiration; Ventilation ~l Bronchi. acute res~iratowdistress associated with - postpkumonectomy bronchopleural fistula, 567 endobronchial tamponade in management of massive hemoptysis, 589 regional constriction in asthma, 715 Bronchial neoplasms: See also Carcinoma, bronchogenic thin-walled cavitary bronchiolar carcinoma, 797 Bronchial stenosis, endobronchial tuberculosis progressing to, 537 Bronchitis, dilatation of airways after metaproterenol sulfate inhalation, 205 Bronchodilators, components of chronotropic actions of aminophylline, 24 dose-related dilatation after metaproterenol sulfate inhalation, 205 new oral beta adrenoreceptor stimulant, Thll65a. 460 Bronchopulmonary aspergillosis, allergic, with obstruction of upper respiratory tract, 788 Bronchoscopy, bronchospasm induced by, 565 teaching model for, 72 Bronchoscopy, fiberoptic diagnosis of gastric aspiration by, 458 endobronchial tuberculosis progressing to bronchial stenosis, 537 flexible, deaths associated with, 200 and butorphanol.

Ru-Hist Forte Tablets also contains Povidone, Microcrystalline Cellulose, Sodium Starch Glycolate and Magnesium Stearate. Pyrilamine Maleate is an antihistaminic that occurs as a white crystalline powder, usually having a faint odor, its solutions are acid to litmus, it is very soluble in water, freely soluble in alcohol and chloroform, and slight soluble in ether and benzene. The chemical name is 1-2 - Ethanediamine, N - [ 4-methoxyphenyl ; methyl] -N', N'- dimethyl -N2 - pyridinyl -, Z ; -2 - butenedioate 1: ; . Phenylephrine hydrochloride is an adrenergic that occurs as white or practically white, odorless crystals, having a bitter taste. It is freely soluble in water and in alcohol. It is affected by light. The chemical name is Benzenemethanol, 3-hydroxy--[ methylamino ; methyl]-, hydrochloride R ; -. Chlorpheniramine Maleate is an antihistamine that occurs as a white, odorless crystalline powder. Its solutions have a PH between 4 and 5. It is freely soluble in water, soluble in alcohol and chloroform, and slightly soluble in ether and benzene. The chemical name is 2-Pyridinepropanamine, -4 -chlorophenyl ; -N, Ndimethyl-, Z ; -2-butenedioate 1: ; . CLINICAL PHARMACOLOGY General: The time release properties of this drug prolongs the duration of action of its individual ingredients Pyrilamine Maleate: Pyrilamine is an antihistamine belonging to the ethylenediamine class. Pyrilamine is a highly effective H1 blocker which possesses local anthesthetic activity. Pyrilamine antagonizes most of the smooth muscle stimulating actions of histamine on the H1 receptors of the gastrointestinal tract, blood vessels and bronchial muscle. It also antagonizes the actions of histamine that result in increased capillary permeability and the formation of edema. Pyrilamine has a duration of action of 4 to hours in clinical studies. Phenylephrine HCl: Phenylephrine is a potent postsynaptic alpha-receptor agonist with little effect on beta receptors of the heart. Phenylephrine has no effect on the beta-adrenergic receptors of the bronchi or peripheral blood vessels. A direct action at receptors accounts for the greater part of it effects. Only a small part being due to its ability to release norepinephrine. Therapeutic doses of Phenylephrine mainly cause vasoconstriction. It increases resistance, and to a lesser extent, decreases capacitance of blood vessels. Total peripheral resistance is increased resulting in increased systolic and diastolic blood pressure. Pulmonary arterial pressure is usually increased and renal blood flow is usually decreased. Following oral administration of Phenylephrine, constriction of blood vessels in the nasal mucosa relieves nasal congestion associated with allergy or head colds. Following oral administration of Phenylephrine, nasal decongestion may occur within 1 to 20 minutes and may persist for up to 4 hours. Phenylephrine is irregularly absorbed from and readily metabolized in the gastrointestinal tract. Phenylephrine is metabolized in the liver and intestine by monoamine oxidase. The metabolites and their route and rate of excretion have not been identified. The pharmacological action of Phenylephrine is terminated at least partially by uptake of the drug into the tissues. Chlorpheniramine Maleate : Chlorpheniramine is an antihistamine belonging to the alkylamine class. It possesses anticholinergic and sedative effects. Antihistamines appear to compete with histamine for H1 cell receptor sites on effector cells. Chlorpheniramine maleate does not prevent the release of histamine in response to injury, drugs or antigens. Antihistamines effectively block most smooth muscle responses to histamine-liberating drugs. Chlorpheniramine is readily absorbed from the gastrointestinal tract and has a duration of 4 to hours. Plasma half-life is approximately 22 hours. Degradation products of chlorpheniramine metabolic transformation by the liver are almost completely excreted in 24 hours via the kidney. The alkamines of which chlorpheniramine is the prototype, are among the most potent H1 blockers. Although not so prone as others to cause drowsiness, a significant proportion of patients do experience this effect. CNS stimulation is more common in chlorpheniramine than in other groups of H1 blockers. INDICATIONS AND USAGE: Ru-Hist Forte Tablets are indicated for symptomatic relief of seasonal and perennial allergic rhinitis, and vasomotor rhinitis. CONTRAINDICATIONS: Hypersensitivity to any of the ingredients. Patients known to be sensitive to other sympathomimetic amines may exhibit cross sensitivity with this drug. Ru-Hist Forte Tablets are contraindicated in patients with severe hypertension, severe coronary artery disease and patients on monoamine oxidase MAO ; inhibitor therapy. It is also contraindicated in patients with diabetes or hyperthyroidism. Antihistamines should not be administered to premature or newborn infants or be used to treat lower respiratory tract symptoms or asthma. WARNINGS: Phenylephrine Hydrochloride: Sympathomimetic amines should be used with considerable caution in patients with hypertension, ischemic heart disease, diabetes mellitus, increased intraocular pressure, hyperthyroidism or prostatic hypertrophy. Sympathomimetics may produce central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension. DO NOT EXCEED RECOMMENDED DOSAGE. Hypertensive crises could occur with concurrent use of Phenylephrine and monoamine oxidase MAO ; inhibitors, indomethazine or with beta blockers and methyldopa. If a Hypertensive crisis occurs, this drug should be discontinued immediately and therapy to lower blood pressure should be instituted. Fever should be managed by means of external cooling. The elderly approximately sixty years or older ; are more likely to have adverse reactions to sympathomimetic. Over dosage of sympathomimetics in this age group may cause hallucinations, convulsions, CNS depressions and death. Therefore, safe use of a short-acting sympathomimetic should be demonstrated in the individual elderly patient before considering the use of a sustained-release formulation. Pyrilamine Maleate and Chlorpheniramine Maleate: Antihistamines should be used with considerable caution in patients with narrow angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, bladder neck obstruction. In children and infants, over dosage may cause hallucinations, convulsions or death. In adults, antihistamines may diminish mental alertness. Chlorpheniramine Maleate has additive effects with alcohol and other CNS depressants hypnotics, sedatives, tranquilizers, etc. ; Patients should be warned about engaging in activities requiring mental alertness, such as driving a car or operating appliances, machinery, etc. General: Antihistamines have an atropine-like action and therefore should be used with caution in patients with a history. Once the diagnosis of ACTH syndrome is established by demonstrating ACTH-dependent hypercortisolemia in the absence of a petrosal to peripheral gradient of ACTH, a screen for biochemical markers is useful to detect possible sources of ectopic ACTH production. Next, tumor localization studies can be done, recognizing that in some patients with clinically occult tumors, the diagnosis may be difficult to establish at any one point in time. More than 90% of patients with ectopic ACTH tumors harbor tumors of the neuroendocrine system, whether overt or occult. These tumors are found either in the chest or abdomen. In the series by Jex et al., 14 25 patients with ectopic ACTH production were found to harbor tumors in the chest 40 ; . Similarly, in the series of Howlett et al. 33 ; , 11 16 were localized in the chest and in the NIH series 41 ; 13 19 had tumors in these areas. In our 12 patients, six had tumors localized to the thorax. All patients presented with bilaterally enlarged adrenal glands on the abdominal CT scan, but beyond that no one localization technique was found to be universally successful 58 ; . A. Chest x-rays When the data from Jex et al. 40 ; , Howlett et al. 33 ; , and our own studies 58 ; were pooled, seven of nine small cell bronchial carcinomas were clearly visible on initial chest x-ray. In the remaining two patients, the presence of bronchial carcinoma was made postmortem. In the 15 patients with bronchial carcinoids, chest x-rays PA and lateral ; were normal in all but three one patient with lung metastases ; . In Howlett's series 33 ; , two of six patients with bronchial carcinoids required 3 months and 4.5 yr, respectively, before the small tumor became radiographically visible. In the Jex series 40 ; , four of seven patients developed positive chest x-rays after bilateral adrenalectomy had been performed. In the remaining three, only the CT scan of the chest allowed a definitive diagnosis. In the total series, postmortem diagnosis was made in three patients, including one patient from our series who underwent transsphenoidal pituitary exploration. Thymic enlargement was found in three of seven cases of thymic carcinoids via routine chest x-rays, as shown in Fig. 6. Finally, in rare and isolated cases, chest x-rays demonstrated metastatic disease [i.e. in the patient of Jex et al. 40 ; with ovarian cancer]. Thus, routine PA and lateral chest x-rays can usually detect SCLCs with overt Cushing's syndrome and some thymic carcinoids, but in the majority of cases, particularly in patients with occult tumors, normal chest x-rays are generally observed and byetta. J.; McGlnn. J. T., and Burbank. B.: The Treatment of the Acute Asthmatic Attack with an Oral Alcohol-Water Solution of Theophylilne Elixophytlin ; , Am. J. Med. Sc. 234: 28 July ; 1967.2. Greenbaum, J.: Clinical Evaluation of Elluophyllin and Choline Theophyllinate In the Management of Acute and Chronic Asthma, Ann. Allergy. 16: 312 May-June ; 1958. 3. Spielman. A.: Comparative Effectiveness of an Alcohol-Water Solution of Theophylline Elixophyllln ; . Aicohoi'Water Solution and Theophylline Solution for the Oral Treatment of Acute Bronchial Asthma, J. Allergy, 30: Jan-Feb. ; 1969. 4. Kessler. F.: ClinIcal Experience with an Oral. Rapidly-Acting. Thanphylllne Preparation, Cons. S.M.J. 21: 296 Mar. ; 1957. Estlmste based on mall survey, data on file at Sherman Laboratories and bronchial.